Notably, high levels of B7-H3 expression in NSCLC, RCC, CRC, and prostate cancer are correlated with disease progression (Li et al., 2014; Jin et al., 2015; Benzon et al., 2017; Mao et al., 2017). Here, CD276 is linked to prostate cancer.